HIV-2 virus variants

Abstract: HIV-2 virus variants, namely virus HIV D205, which can be cloned from the corresponding virus isolate HIV D205 (ECACC V 87122304) and its RNA or RNA-fragments and DNA and DNA-fragments derived therefrom and/or proteins and the use thereof for diagnostics and therapy.

Description: The present invention relates to HIV D205 a HIV-2 virus variant that may be cloned from the corresponding virus isolate HIV D205 (ECACC V 87122304). "Molecular cloning of two West African human immunodeficiency virus type 2 isolates which replicate well on macrophages: a Gambian isolate from a case of neurologic aquired immunodeficiency syndrome, and a highly divergent Ghanesian isolate" (Kühnel, H., v. Briesen, H., Dietrich, U., Adamski, M., Mix, D., Biesert, L. Kreutz, R., Immelmann, A., Henco, K., Meichsner, Ch., Andreesen, R., Gelderblom, H. & Rübsamen-Waigmann, H., 1989, Proc. Natl. Acad. Sci. 86, 4, 2383-2387. In diagnostics, two criteria are demanded to be met, namely specifity and sensitivity for the antigen to be detected. In the diagnostics of AIDS the demand for specifity can certainly be complied with by using the isolates HTLV-III B and LAV-2 (Guyader, M. et al., "Nature" 326 , 1987, 662-669) in order to delimit HIV infections from other infections and, thus, to make a rough assignment into the classes of "HIV-2-related infections" or "HIV-1-related infections". However, a problem is constituted by the sensitivity of the diagnosis. In the range of the so-called seroconversion, i.e. the initial occurrence of the antibody in the infected person, a reduction in sensitivity implies an increase in the number of "falsely negative" test results. Accordingly, it is one main goal to shorten the period between an infection and the detectability of this infection as much as possible by improving the test sensitivity. A decreased cross reactivity, in the practice of the widely employed ELISA diagnostics, is manifested, for example, in a reduced sensitivity. Thus, the use of the described HIV-1 isolate means about an average reduction of the test sensitivity against HIV-2 sera by the factor of 100 to 1000, whereas the isolate HTLV-III B enables almost no detection to be accomplished anymore. A disastrous principle of the diseases caused by HIV resides in the fact that there is not only one type of each of HIV-1 and HIV-2 virus phenotypes and genotypes. What is to be premised is rather a large group of related viruses, possible even populations which by no way are strictly separated from each other but continuously penetrate one another and undergo some evolutionary development to a more and more increasing divergence, while at the same time they begin by recombination events to exchange between each other parts of the genom. Thus, the existing HIV species form a broad continuous population level in which there are no narrowly delimited subpopulations of one virus variant. There is rather to presumed that a continuum exists which is subject to permanent fluctuations with time. The classified virus variants HIV-1 and HIV-2 are representatives of the diffusely delimited subpopulations having a relative low degree of relationship, which is manifested by only a partial cross reactivity. On the other hand, there are variants of the HIV-1 group (Rübsamen-Waigmann, H. et al., "AIDS-Forschung" 10 , 1987, 572-575; Rübsamen-Waigmann, H. et al., J. Med. Virol. 19 , 1986, 335-344; v. Briesen, H. et al., J. Med. Virol. 23 , 1987, 51-66), which do significantly stronger cross-react with HIV-2 than the first characterized HIV-1 isolate itself (Hahn, B. et al., "Nature" 312 , 1984, 166-169). A commercial product consisting of such an isolate diagnoses distinctly more sera as being HIV-2 positive than does the described standard isolate HTLV-III B . An ideal diagnostic or therapeutic product should contain at least one representative from the populations as significantly biologically distinguished from one another. HIV-1 viruses in a multitude of highly polymorphic genetic mutants may cause different diseases such as ARC, LAS, AIDS and encephalopathies (ARC: AIDS-related complex, LAS: lymphadenopathy syndrome, AIDS: acquired immune deficiency syndrom). Cloned virus variants are distinguished in sequence and restriction pattern, even if they have been isolated at the same time, at the same place and even from the same patient (Rübsamen, H. et al., 1986). It could be shown that virus variants of the HIV-1 type are distinguished in some virus antigens up to about 15%. HIV-2's are even different in more than 40% of the aminoacids in some antigens, substitutions, insertions and deletions having been considered (Guyader, M. et al., 1987; Rabson, A.B. & Martin, M.A. "Cell" 40 , 1985, 477-480). The present invention provides a variant of the HIV-2 virus. The variant HIV-2 D205 was isolated from a clinically asymptomatic patient. The virus isolate proved to be diagnostic agents, relative to DNA/RNA as well as relative to the virus antigens, for serologically and directly identifying infections by the type HIV-2 in the pre-AIDS and AIDS stages. The virus isolate according to the invention comprises viruses and proviruses, the characteristics of which are identical to those of the disclosed restriction map and the sequence of the cloned partial regions (Figures 1-4). Moreover, the virus isolate comprises variants which are distinguished from the viruses and proviruses described above in that they are different in their nucleotide sequences from the above-described viruses only by up to 5%, and preferably by 2%, particularly preferred by 1%. The virus variant according to the invention may cause lymphadenopathies (further designated as LAS/AIDS). Claimed according to the invention are also expression products of said virus variant, and more particularly antigens, preferably in accumulated or pure form, and processes for producing said expression products. The expression products are intended to include all polypeptides in glycosylated and or meristylated forms which have been coded on the positive or negative strand of the cloned RNA or DNA. A further preferred embodiment consists of cloned DNA sequences capable of hybridizing with genomic RNA and DNA of the virus variant. Claimed according to the invention are stable gene probes containing such DNA sequences which are suitable for the detection of hybridization of those and other HIV variants or related viruses or DNA proviruses in samples to be investigated, more particularly biological or semi-synthetic samples. A further preferred embodiment of the invention is comprised by virus variant the RNA/DNA of which or respective fragments will hybridize to the virus variants according to the invention under stringent conditions, more particularly c-DNA, genomic DNA, recombinant DNA, synthetic DNA or fragments thereof. These are understood to include variants or fragments which exhibit deletions and insertions in comparison to the virus variant according to the invention. Stringent conditions of hybridization and washing are meant to be understood as those conditions which ensue by way of experiment or calculation if the melting point of the 100% homologous nucleic acid complexes in conditions of hybridization and washing will be fallen below by not more than 5 °C under the buffer conditions employed. Also claimed according to the invention are cloned synthetic gene probes which may be derived from the above-described virus variants and can be augmented in vector systems in eukaryotes or prokaryotes. The described cloned DNA fragments are suitable for hybridization with complementary nucleic acids (DNA/RNA) for the purpose of diagnostic detection of the virus variants. The diagnostic tests according to the invention are carried out by using DNA or RNA probes. The probes are radioactive or have been labelled with fluorescent bio- or chemiluminescent groups or enzymes or are specifically detectable with enzymes via coupled reaction systems. The hybridizations may be effected in a homogeneous phase of a solution or in a heterogeneous phase with solid-immobilized nucleic acids, while the solid may be a membrane, particle, cell or tissue, so that the hybridization may also be effected in situ . From the virus isolate claimed according to the invention, the corresponding DNA sequences (Figure 1) may be cloned in E. coli bacteria by establishing a genomic lambda-gene bank, starting from the DNA of the lymphocytes infected with the virus isolate. The desired clones are obtained by carrying out a plaque-screening with STLV-III sequences of the gag-pol range. In a more specifical way, there may be used as a probe a DNA derived from the published sequence HIV-2 ROD (Guyader, M. et al., "Nature" 326 , 1987, 662-669), or a DNA probe derived from the partial sequences of the isolate HIV-2 D205 according to the invention. The diagnostic method based on the use of the viruses claimed according to the invention comprises the following steps: Extraction of RNA or DNA from biological samples, possibly enzymatic processing by restriction enzymes, separation by gel electrophoresis and/or direct blot methods for nucleic acid-binding carriers, and subsequent hybridization with parts of the cloned fragments of the claimed viruses. Hybridizations may also be directly carried out in chemically treated cells or tissues. Therein the origin of the tissues or liquids is insiginificant. Specifically, a process for the in vitro detection of antibodies against expression products of the viruses of the present invention is characterized in that the expression products or parts thereof of the viruses are detected by means of immunological methods. The process is characterized in that the expression products are proteins, peptides or parts thereof which have been coded within the meaning of an open reading frame on the DNA of the proviral partial sequences as characterized in claim 1 and are prepared by synthetic or biosynthetic processes. The process is further characterized in that previously a definite amount or a combination of expression products or parts thereof are fixed on microtiter plates, whereupon subsequently biological samples, diluted or undiluted, are contacted with the coated microtiter plates and after incubation and sequential washing steps can be identified by means of a detecting reagent or of labelled anti-HIV antibodies. Alternatively, filter strips and plastic strips or rods are used instead of microtiter plates, wherein the expression products of the viruses have been fixed at respective specific positions by isolated application of the different antigens. The expression products can also be separated by gel electrophoresis and then transferred by blotting whereupon incubation with anti-HIV antibodies and the detection thereof are effected. Detection is effected on solid phase carriers to which the antigen determinants have been bonded, with the solid phase carrier consisting of particles. Expression products can be virus antigens derived from in vitro-infected cells, said antigens being contacted with biological test materials as antigens bonded to fixed cells, and that the subsequent antibody bonding can be determined with immunological detection reagents by means of an apparatus, for example with a cytofluorimeter, or visually. The antigens can be determined by competitive ELISA. HIV-related nucleic acids (DNA and RNA) can be detected in biological samples, cells and in isolated form by using the nucleic acids according to the present invention. Expression products can be supplemented by materials which are related to other HIV variants, which, however, are distinguished in their biological properties from the materials of the isolates of the present invention. For diagnostic and therapeutic goals the described DNA segments may also be employed for expressing coded antigens H . Therein the DNA segments under aimed control of regulation sequences are introduced into pro- or eukaryotic target cells, tissues or multiple-cell organisms to stimulate these to produce the accordingly coded antigens, parts thereof or combinations thereof with alien antigens. Antigens can be detected via the reaction with anti-HIV-2 antibodies, more particularly from the sera of the respective patients. Antigens having longer open reading frames (>50 amino acids) lend themselves as well those which are subject to splicing processes on the RNA level and are only thus composed to form the longer open reading frames. According to the invention further claimed are polypeptides originating from the cloned virus variant according to the invention to detect such antigens in the material under investigation which contain similar antigen determinants and thereby do immunologically cross-react. This is particularly suitable for the diagnosis of AIDS and pre-AIDS of virus carriers or asymptomatic virus carriers or virus products, respectively, which are derived from blood. Also the serological detection of the antibodies directed against these antigenic polypeptides as expression products of the virus claimed according to the invention becomes possible by employing conventional systems such as ELISA. The immunogenic polypeptides may be used as protective polypeptides as vaccines to cause protection against AIDS infections. The virus isolates according to the invention and the products derived therefom may be combined with other isolates of the partial population HIV-2 in test systems, that is with those which are as far remote as possible in the described population level such as for example, the isolate HIV-2 ROD (Guyader, M. et al., 1987). Thereby it becomes possible sensitively to detect also populations of remote relationship in one test. The virus variant according to the invention is highly different from the spectrum of the HIV-1 variants and have a closer molecular relationship to the HIV-2 virus described by Guyader, although they are distinguished therefrom to a significant extent (Figure 1). Also the biological properties are clearly distinguished from the described HIV-2 isolate. Thus, the variant according to the invention, for the effective in vitro replication, prefers cells which are derived from myeloidic lines. On the contrary, the virus poorly reproduces itself on lymphocytic lines. A sample of the virus claimed according to the invention has been deposited in the form of its isolate at the European Collection of Animal Cell Cultures under the designation HIV D205 (V 87122304) according to the Budapest Treaty. Figure 1 shows the restriction maps of the virus isolate according to the invention in comparison to known HIV sequences. Figure 2 shows the partial nucleotide sequences of HIV-D205 (corresponding to clone HIV-2 A7.1 of Figure 2). Figure 3 shows the sequence homology of HIV-2 D205,7 compared to the HIV/SIV group (gene level; nt/aa). Figure 4 shows a nucleotide sequence comparison of HIV-2 D205 with HIV and SIV strains (in % homology). Experimental results and characteristics of HIV-D205 are described in Kühnel, H. et al. (1989) Proc. Natl. Acad. Sci. 86, 4, 2383-2387. The sequence of HIV-D205 shows a lot of so-called "open reading frames". Most of these reading frames can be related to in vivo expressed proteins/antigens by comparison of homologies to previously described HIV-viruses, by comparison of Western blots performed with HIV-D205 antigens derived from infected HUT78 or U937 cells and by probing with sera from the corresponding patients and reference sera. Other open reading frames are not identified on the level of their expressed antigens defined by function or antibody staining on Western Blot. However, they can be expressed under some circumstances in vivo . Other reading frames, even short ones, can be expressed as well in a way difficult to predict solely on the basis of nucleic acid sequencing data because of splicing processes. Antigenic determinants on expressed proteins as they are important for the biological function, for target antigens in diagnostics or for immunization are spread all over the expressed linear protein sequence. Parts of these sequences can have more general antigenic properties than others as can be shown by peptide screening/ mapping for antigenic sites. These sites can be expressed as single epitopes or as continuous polypeptide or in a version of in vitro or synthetically spliced antigens. Antigenicity of the expressed products can be demonstrated by antigen fixation and blotting in the Western Blot assay. Constructions for antigen expression in E. coli can be done by using conventional techniques using synthetic genes, restriction fragments from cloned viral genome segments, trimming products thereof by using exonuclease or DNase I or by using sequence specific synthetic primers defining the desired 5' and 3' end of the fragment to be expressed together with appropriate restriction sites. These restriction sites can easily be used for ligation into a panel of expression vectors of different organisms like those derived from PLc24 (Remault et al. 1981 Gene 15, 81-83) with multicloning sites (pEX). The expressed antigens were shown to specifically react with patients' sera. The p27(24) from gag of HIV-D205 react very sensitively with both typical HIV-1 sera and typical HIV-2 sera (see Kühnel et al).

Claims: A virus isolate HIV-2 D205 (ECACC V 87122304), which prefers cells which are derived from myeloidic cells for in vitro replication. DNA of the proviral partial sequences of the virus isolate of claim 1 according to the endonuclease restriction-site characteristics of figure 1. cDNA differing from the nucleotide sequence of the virus isolates according to claim 1 by up to 5%. Viral RNA differing from the nucleotide sequence of the virus isolates according to claim 1 by up to 5%. Recombinant DNA containing DNA as defined in claims 2 and 3. DNA or RNA according to any one of the claims 2 to 5, wherein the DNA or RNA is present as hybrid with complementary labelled DNA or RNA strands. DNA according to any one of the claims 2, 3, 5 and/or 6, characterized in that it is complementary to viral DNA. Expression products of the virus isolate according to claim 1. Expression products according to claim 8, characterized in that the proteins or peptides have been coded by an open reading frame on the DNA according to claim 2. A process for the in vitro detection of antibodies against expression products of the viruses according to claim 8, characterized in that the expression products of the viruses are detected by means of immunological methods. The process according to claim 10, characterized in that the expression products are proteins or peptides which are coded by an open reading frame of the DNA according to claim 2 and are prepared by synthetic or biosynthetic processes. The process according to claims 10 or 11, characterized in that previously a definite amount of a combination of expression products are fixed on microtiter plates, whereupon subsequently biological samples, diluted or undiluted, are contacted with the coated microtiter plates and after incubation and sequential washing steps can be identified by means of a detecting reagent or of labelled anti-HIV antibodies. The process according to any one of claims 10 to 12, characterized in that filter strips and plastic strips or rods are used instead of microtiter plates, wherein the expression products of the viruses have been fixed at respective specific positions by isolated application of the different antigens. The process according to claim 13, characterized in that the expression products are separated by gel electrophoresis and then transferred by blotting whereupon incubation with anti-HIV antibodies and the detection thereof are effected. The process according to any one of claims 10 to 14, characterized in that the detection is effected on solid phase carriers to which the antigen determinants have been bonded. the solid phase carrier consisting of particles. The process according to any one of claims 10 to 15, characterized in that the expression products are virus antigens derived from in vitro -infected cells, said antigens being contacted with biological test materials as antigens bonded to fixed cells, and that the subsequent antibody bonding can be determined with immunological detection reagents by means of an apparatus, for example with a cytofluorimeter, or visually. The process according to claim 16, characterized in that the antigens are determined by competitive ELISA. A process for detecting HIV-related nucleic acids (DNA and RNA) in biological samples, cells and in isolated form by using the nucleic acids according to claims 2 to 7. The process according to any one of claims 10 to 18, characterized in that the expression products are supplemented by materials which are related to other HIV variants, which, however, are distinguished in their biological properties from the expression products of the isolate according to claim 1. Immunogenic composition, containing expression products of claim 8. The immunogenic composition according to claim 20, characterized in that one antigen is the total membrane antigen. Antibodies, and more specifically monoclonal antibodies, specifically directed against expression products of the virus isolate according to claim 1. Isolated Cells which have been transformed with nucleic acids according to any one of claims 2 to 7. Isolated Cells which have been infected with the virus isolate according to claim 1.

Inventors: ADAMSKI MICHALINA, DIETRICH DR URSULA, HENCO DR KARSTEN, IMMELMANN DR ANDREAS, KUEHNEL DR HERBERT, RUEBSAMEN-WAIGMANN PROF DR HEL, VON BRIESEN HAGEN, ADAMSKI, MICHALINA, DIETRICH, DR. URSULA, HENCO, DR. KARSTEN, IMMELMANN, DR. ANDREAS, KUEHNEL, DR. HERBERT, RUEBSAMEN-WAIGMANN, PROF. DR. HELGA, VON BRIESEN, HAGEN, Kühnel, Dr. Herbert, Rübsamen-Waigmann, Prof. Dr. Helga
Applicants: CHEMOTHERAPEUTISCHES FORSCHUNG, QIAGEN GMBH, CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS
Application year: 1989
Main classification: C12N15
IPC codes: C07K14, A61K38, C12N15, C12N7